Comparison of the Efficacy and Safety of Flunarizine to Propranolol in the Prophylaxis of Migraine

Autor:	Marek Gawel, J Kreeft, D Simard, R F Nelson, W S Arnott
Rok vydání:	1992
Předmět:	business.industry Antagonist General Medicine Propranolol medicine.disease Placebo law.invention Blood pressure Neurology Migraine Randomized controlled trial law Anesthesia Heart rate medicine Neurology (clinical) business Flunarizine medicine.drug
Zdroj:	Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 19:340-345
ISSN:	2057-0155 0317-1671
DOI:	10.1017/s0317167100041962
Popis:	This study was designed to compare flunarizine, a cerebro-specific calcium channel antagonist, and propranolol in the prophylaxis of migraine with or without aura. Following a 1 month single-blind placebo baseline period, 94 patients were equitably randomised under double-blind conditions to take flunarizine 10 mg daily or propranolol 80 mg twice daily for 4 months. Both treatments led to a significant reduction in the frequency of migraines and use of rescue analgesics with a significantly greater decrease in number of attacks for flunarizine after 1 and 4 months. Neither treatment affected the severity nor duration of migraines. Overall, 67% of flunarizine patients and 51 % of propranolol patients responded positively. Propranolol significantly reduced blood pressure and heart rate; flunarizine had no effect on cardiovascular function. Weight gain was noted with both treatments. Flunarizine is at least as effective as propranolol in the prophylactic treatment of migraine and may have a better safety profile.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1ffec21e1a175519c8dc4bb760ecea7d https://doi.org/10.1017/s0317167100041962 Zobrazit plný text záznamu